← Back to all trials
Completed
NCT04578834
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Conditions: IgA Nephropathy
Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 517
Sponsor: Novartis Pharmaceuticals
Location: AZ Kidney Dise and Hypertension Ctr Glendale Arizona
Summary
The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
Eligibility Criteria
Inclusion Criteria:
* Male and female patients ≥ 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows:
* For patients eGFR\* ≥ 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required.
* For patients with eGFR\* 30 to \
Source: ClinicalTrials.gov (NCT04578834). StuddyBuddy aggregates publicly available trial information.